	Page <u>1</u> of <u>3</u>
Serial No.:	

OTT	E SO	
MAR 2	1 2002	
\z.		

[1 2002					₹		D 1 - f 2		
FORM PTO-1449 INFORMATION DISCLOSURE CITATION			mey Docket:	Serial No.: 09/995,522		Page <u>1</u> of <u>3</u>				
		Appl	icant:	HATATCH	70 1	±3 7 7				
INFORMA	ATION D	VISCLOSURE CIT		Nove	g Date: ember 28, 2001	Group Art Unit: To Be Assigned	유	ĭ ∏		
			U.S	S. PAT	ENT DOCUMENTS			\$ ()		
Examiner Initial		Patent Number	Issue Da	te	Name	Class	Suri- Ciass	oFiling Date		
							1600/	22000		
							22			
					PATENT DOCUMENTS					
Examiner Initial		Patent Number	Publicati Date	on	Country	Class	Sub- Class	Translation		
								Yes No		
			aur .		-			☐ Yes ☐ No		
					(Including Author, Title, Da					
L/A	1	with Human Carcin	noma Cells,	Grow	eactivities of Polyclonal and n <i>In Vitro</i> and in a Zenograft	Model", Int. J. Car	ncer, 72:119	-127.		
	2				Mouse-Antibody Response I its is Associated with Longer					
	3	J.A. Francisco et al Blood, 89-4493-45	., 1997, "In 00.	vivo E	Efficacy and Toxicity of a Si	ngle-Chain Immun	otoxin Targe	eted to CD40",		
	4				nting Protein Doses of Chime tients: A Phase I Study", <u>CA</u>					
	5	E. Kievit et al., 1997, "Determination of Tumor-Related Factors of Influence on the Uptake of the Monoclonal Antibody 323/A3 in Experimental Human Ovarian Cancer", Int. J. Cancer, 71:237-245.								
	6	K.O. Lloyd et al., 1	K.O. Lloyd et al., 1997, "Isolation and Characterization of Ovarian Cancer Antigen CA 125 using a New Monoclonal Antibody (VK-8): Identification as a Mucin-Type Molecule", Int. J. Cancer, 71:842-850.							
	7	A. van Dalen, 1999, "BR-MA, OM-MA, GI-MA and CEA: Clinical Evaluation Using the IMMULITE Analyzer", Tumor Biology, 20:117-129.								
	8	G. Gebauer et al., 1999, "IMMULITE® OM-MA Assay: A Useful Diagnostic Tool in Patients with Benign and Malignant Ovarian Tumors", Anticancer Research, 19:2535-2536.								
	9	S. Ozaki et al., 1997, "Immunotherapy of Multiple Myeloma with a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24", <u>Blood</u> , 90:3179-3186.								
	10	S.P. Treon et al., 1999, "Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone", <u>Blood</u> , 93:1287-1298.								
	11	K. Ono et al., 1999, "The humanized anti-HM1.24 antibody effectively kills multiple myeolma cells by human effector cell-mediated cytotoxicity", Mol. Immunology, 36:387-395.								
	12	G. Teoh et al., 199	8, "The 86-	kD Sul	bunit of Ku Autoantigen Med		nd Heteroty	pic Adhesion		
11,	1	of Multiple Myeloma Cells", <u>J. Clin. Invest.</u> , 101:1379-1388. W.C.A.M. Buijs et al., 1998, "Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian								
4	13	1561.	patients after intraperitoneal and intravenous administration", Eur. J. Nuclear Medicine, 25:1552-							
hop	14	M.A. Bookman, 19 25:381-396.	98, "Biolog	gical T	herapy of Ovarian Cancer: C	Current Directions",	Seminars in	n Oncology,		
Examiner	·				Date Considered	9/11/97				

Initial if reference considered, whether or not citation is in conformance with MPEP §609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant. EXAMINER:



Attorney Docket: Serial No.: 3828-4000US1 Applicant:

09/995,522

INFORMATION DISCLOSURE CITATION

Cohava GELBER Filing Date:

Group Art Unit:

MAR 2 6 2002

				vember 28, 2001	To Be Assigned				
			U.S. PA	TENT DOCUMENTS	- -	GOU OENT	ER 1600/29		
Examiner									
Initial		Patent Number	Issue Date	Name	Class	Class	Filing Date		
			FOREIGN	PATENT DOCUMENTS					
Examiner			Publication			Sub-			
Initial		Patent Number	Date	Country	Class	Class	Translation		
							☐ Yes ☐ No		
							Yes No		
				S (Including Author, Title,)					
M	15			of Epithelial Ovarian-Cance		ns Involved	in Immune		
wh	13	Complexes by Mor	noclonal Antibod	lies", Tumor Biology, 19:1-	11.				
	16			nacokinetics and radiation d			clonal		
4	10			patients", <u>Nuclear Medicine</u>					
		E. Kievit et al., 199	7, "Comparison	of the Biodistribution and the	ne Efficacy of Mono	clonal Antib	ody 323/A3		
\	17	Labeled with Eithe	r ¹³¹ I or ¹⁸⁶ Re in 1	Human Ovarian Cancer Xer	ografts", <u>Int. J. Radi</u>	ation Oncol	<u>ogy Biol.</u>		
		Phys., 38:813-823.							
1	18	M. Hartman et al.,	1999, "MUC1 Is	oform Specific Monoclonal	Antibody 6E6/2 Det	ects Prefere	ntial		
- \	18	Expression of the N	Novel MUC1/Y I	Protein in Breast and Ovaria	n Cancer", Int. J. Car	ncer, 82:256	-267.		
	10	M.L. Grossbard et	al., 1998, "Anti-	B4-blocked ricin: a phase II	trial of 7 day continu	uous infusio	n in patients		
1	19	with multiple myeloma", British Journal of Haematology, 102:509-515.							
	1	H. Bertz et al., 1997, "Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow							
1	20	transplantation (BMT): evidence for a graft-versus-myeloma effect", <u>Leukemia</u> , 11:281-283.							
	-						Macrophage		
	21	J.L. Hornick et al., 1997, "Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 with Specificity for B-Cell Malignancies Exhibit Enhanced							
4		Effector Functions while Retaining Tumor Targeting Properties", <u>Blood</u> , 89:4437-4447.							
		D.G. Maloney et al., 1999, "Antibody Therapy for Treatment of Multiple Myeloma", Seminars in Hematology							
	22	(Suppl)., 36:30-33.		ay Therapy for Treatment of	i wintiple wrycioma	, <u>Bernmars</u>	militematolog		
	-			l P on everession in multipl	a mualoma natients	at primary d	ingnosis and		
1	23	V. Nuessler et al., 1997, "Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease", <u>Leukemia (Suppl.)</u> , 11:S10-S14.							
	24			nt of Multiple Myeloma in I		P. A	- 11,150 164		
	24								
	25			ted Superantigens for Immu	notherapy of Haema	topotetic Tu	mors, <u>vox</u>		
		Sanguinis, 74:483-487. M.G. Bosselblum et al. 1000 "Blood I Study of 90V labeled B.72.3 Interpretational Administratoria in Patients.							
1	26	M.G. Rosenblum et al., 1999, "Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administratoin in Patients							
1	26	with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity",							
+ -		Clinical Cancer Research, 5:953-961. R.H.M. Verheijen et al., 1999, "CA 125: fundamental and clinical aspects", Seminars in Cancer Biology,							
1/	27	1	et al., 1999, "CA	125: fundamental and clinic	cal aspects", <u>Semina</u> i	rs in Cancer	Biology,		
1/	<u> </u>	9:117-124.							
	28	G. Fleckenstein et al., 1998, "Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on							
W	20	gynaecological cancer", Medical Oncology, 15:212-221.							
MD	29	E. Kievit et al., 1998, "[186Re]-labeled Mouse and Chimeric Monoclonal Antibody 323/A3: A Comparison of							
ν·γ ¬		the Efficacy in Exp	erimental Huma	n Ovarian Cancer", <u>Nuclear</u>	Medicine & Biology	<u>v, 25:37-4</u> 5.			
xaminer		. 11 -		Date Considered 9/	11/03				
					11/ 5				
		efence considered, whether or		· ·					
		arough citation if not in confo y of this form with next comn							

. /	OIPE									
()	IAR 2 1 20	02 🗳						Page <u>3</u> of <u>3</u>		
FORM PTO-1449				orney Docket:	Serial No.:	Ħ	70			
				8-4000USI	09/995,522	TECH CENTER	loot .			
				olicant: ava GELBER		T CENT				
INFORM	ATION I	DISCLOSURE CIT	ATION		ng Date:	Group Art Unit:	罗艺			
					rember 28, 2001	To Be Assigned	田。			
			U.	S. PAT	TENT DOCUMENTS		_			
Examiner Initial		Patent Number	Issue Da	Pate Name		Class	Sab- Gass Filling Date			
Initial_		ratent Number	135ue Da	ite	Name	Class	1223			
							2900			
		—								
			FORE	IGN I	PATENT DOCUMENTS			- A		
Examiner		Publicati		on			Sub-			
Initial		Patent Number	Date		Country	Class	Class	Translation		
								Yes No		
		OTHE	D DOCUM	LENTE	Carlodina Anthon Title De	40.040		Yes No		
					S (Including Author, Title, Da munotherapy after chemothera		emotherany	alone in the		
100	30							alone in the		
		treatment of advanced ovarian cancer: A matched analysis", <u>Oncology Reports</u> , 5:223-226. B.C. Schultes et al., 1998, "Anti-idiotype induction therapy: anti-CA125 antibodies (AB ₃) mediated tumor								
4	31									
		killing in patients treated with Ovarex mAB B43.13 (Ab ₁), <u>Cancer Immunol. Immunother</u> , 46:201-212. M. Jojovic et al., 1998, "Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-								
	32	mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe								
					Histochemical Journal, 30:723					
	33				l Antibody Targeting of Ovar					
	24	M.F. Federici et al., 1999, "Selection of Carbohydrate Antigens in Human Epithelial Ovarian Cancers as								
	34	Targets for Immunotherapy: Serous and Mucinous Tumors Exhibit Distinctive Patterns of Expression", Int. J.								
-	_	Cancer, 81:193-198. W.G. McCluggage et al., 1998, "Immunocytochemical staining of ovarian cancer cyst aspirates with								
	35			inhibin", Cytopathology, 9:336-342.						
			C.T. VanZaanen et al., 1998, "Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal							
1	36	Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp 130", Leukemia and								
		Lymphoma, 31:551	<u>_ymphoma</u> , 31:551-558.							
	37				ale for adjuvant idiotypic vacc	ination after high-	dose therapy	for multiple		
	31				<u>Transplant</u> , 3:157-63.					
	38		mith et al., 1999, "Immunohistochemically detecting target antigens in patient biopsies for tailoring lonal antibody based cancer therapy", <u>Human Antibodies</u> , 9:61-65.							
							201 (21			
	39 ,				ntibodies", <u>Antibodies: A Lab</u> ng epitopes: It's not as easy as			m. 17.026		
	40	937.	ai., 1999,	Deniii	ng epitopes: It's not as easy as	s it seems, <u>mature</u>	Biotechnoic	igy, 17:930-		
	41		The Carbob	vdrate	Frontier" Biotechnology 7:3	35-40				
	42	P. Knight, 1989, "The Carbohydrate Frontier", <u>Biotechnology</u> , 7:35-40. J.M. Cruse et al., 1995, <u>Illustrated Dictionary of Immunology</u> , p. 22.								
WA	43				ology, Raven Press, NY Chpt					
		, , , , , , , , , , , , , , , , , , , ,								
		11								
Examiner					Date Considered 9/11	73				

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP §609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.